Here’s what you should know:
1. The FTC cleared the acquisition unconditionally.
2. The deal still has a number of regulatory burdens to clear and needs shareholder approval.
3. If Takeda completes the deal, it will be the world’s most indebted drugmaker. To ease the burden, the company has made a series of transactions, including listing its Osaka, Japan-based headquarters for sale.
4. If the deal receives all necessary approvals, it could close in the first half of 2019.
More articles on supply chain:
Joint replacement, spine ASC opens in Southern California
Dr. Paul Chin becomes 1st surgeon in Texas to use Catalyst Orthoscience device: 5 takeaways
5 organizations teaming up to tackle antibiotic resistance in outpatient space— 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
